Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;36(5):1408-1411.
doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24.

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Jean-Jacques Kiladjian  1 , Christoph Klade  2 , Pencho Georgiev  3 , Dorota Krochmalczyk  4 , Liana Gercheva-Kyuchukova  5 , Miklos Egyed  6 , Petr Dulicek  7 , Arpad Illes  8 , Halyna Pylypenko  9 , Lylia Sivcheva  10 , Jiří Mayer  11 , Vera Yablokova  12 , Kurt Krejcy  2 , Victoria Empson  2 , Hans C Hasselbalch  13 , Robert Kralovics  14   15 , Heinz Gisslinger  16 ; PROUD-PV Study Group
Collaborators, Affiliations

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Jean-Jacques Kiladjian et al. Leukemia. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JJK reports grants and personal fees from AOP Orphan, and personal fees from Novartis, BMS/Celgene, Abbvie and PharmaEssentia. CK, KK, and VE report that they are employees of AOP Orphan. JM reports grants from AOP Orphan. RK reports personal fees from AOP Orphan Pharmaceuticals, PharmaEssentia, Qiagen and Novartis and stock ownership in MyeloPro Diagnostics and Research. HH reports Data Monitoring Board honoraria from AOP Orphan and grants from Novartis. HG reports grants and personal fees from AOP Orphan, grants and personal fees from Novartis and personal fees from PharmaEssentia, MyeloPro Diagnostics and Research, Janssen-Cilag, Roche, and Celgene. The remaining authors declare no competing financial interests.

Figures

Fig. 1
Fig. 1. Median JAK2V617F allele burden (%).
Figure 1 shows the median JAK2V617F alle burden (%) during a period of 5 years of treatment. JAK2V617F allele burden was determined every 6 months. Medians were calculated for the last observation carried forward at each timepoint assessed. * Denotes a statistically significant (p < 0.05) difference between the treatment arms.
See this image and copyright information in PMC

References

    1. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72. doi: 10.1182/blood-2008-03-143537. - DOI - PubMed
    1. Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8:94. doi: 10.1038/s41408-018-0133-0. - DOI - PMC - PubMed
    1. Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776–81. doi: 10.1038/leu.2015.326. - DOI - PubMed
    1. Utke Rank C, Weis Bjerrum O, Larsen TS, Kjaer L, de Stricker K, Riley CH, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016;57:348–54.. doi: 10.3109/10428194.2015.1049171. - DOI - PubMed
    1. Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41:5–19. doi: 10.1007/s00281-018-0700-2. - DOI - PMC - PubMed

Publication types